Literature DB >> 22633164

Cutaneous lesion induced by a subcutaneous administration of bortezomib.

Karam M Obeid1, Richard Ferrara, Mamta Sharma.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22633164     DOI: 10.1016/j.clml.2012.05.002

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


× No keyword cloud information.
  6 in total

1.  Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.

Authors:  Tomohiko Kamimura; Toshihiro Miyamoto; Shuichiro Takashima; Noriko Yokota; Yong Chong; Yoshikiyo Ito; Koichi Akashi
Journal:  Int J Hematol       Date:  2012-09-08       Impact factor: 2.490

2.  High incidence and severity of injection site reactions in the first cycle compared with subsequent cycles of subcutaneous bortezomib.

Authors:  Tomohiko Kamimura; Toshihiro Miyamoto; Noriko Yokota; Takatoshi Aoki; Yoshikiyo Ito; Koichi Akashi
Journal:  Int J Hematol       Date:  2013-11-19       Impact factor: 2.490

Review 3.  Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits.

Authors:  Maria Teresa Petrucci; Paola Finsinger; Marta Chisini; Fabiana Gentilini
Journal:  Patient Prefer Adherence       Date:  2014-07-04       Impact factor: 2.711

4.  A case of bortezomib (Velcade)-induced Stevens-Johnson syndrome confirmed by patch test.

Authors:  Gil-Soon Choi; Ho Sup Lee; Hee-Kyoo Kim
Journal:  Asia Pac Allergy       Date:  2021-04-21

5.  The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.

Authors:  Joo Young Jung; Ho Young Kim; Boram Han; Dae Ro Choi; Dae Young Zang; Hyo Jung Kim
Journal:  Biomed Res Int       Date:  2014-06-04       Impact factor: 3.411

6.  Recurrent Body Rash Warranted Second Desensitization With Acyclovir in a Myeloma Patient: A Case Report.

Authors:  Jack T Seki; Pamela Ng; Wallace Lam; Julie Cote; Anca Prica
Journal:  J Clin Med Res       Date:  2017-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.